FDA Drops Lot Code Tracking

Garry, Michael
December 2004
SN: Supermarket News;12/13/2004, Vol. 52 Issue 50, p6
Reports on the decision of the U.S. Food and Drug Administration to cancel tracking manufacturer lot codes in 2004 under the Bioterrorism Act of 2002. Statement issued by Tim Hammonds, CEO of the Food Marketing Institute, on lot code tracking; Terms and conditions of the rules under the Bioterrorism Act; Deadline of compliance among companies based on the ruling.


Related Articles

  • New bioterrorism rules 'strike balance,' says FMI. McTaggart, Jenny // Progressive Grocer;11/1/2003, Vol. 82 Issue 16, p6 

    Provides information on interim bioterrorism rules issued by the U.S. Food and Drug Administration in 2003. Comments from Tim Hammonds, president and CEO of the Food Marketing Institute on the rules; Details of the shorter-prior notice requirements under the rules.

  • Quality overload.  // Pharmaceutical Technology Europe;Jun2011, Vol. 23 Issue 6, p50 

    The article presents some of the experiences encountered by a senior compliance officer. The officer shares their experience on the manufacturing of their nanofilters and their pending approval from the U.S. Food and Drug Administration (FDA). It also presents an experience regarding the number...

  • New Policies Seek to Spur Biopharmaceutical Development. Wechsler, Jill // BioPharm International;Jun2005, Vol. 18 Issue 6, p32 

    Reports on the pharmaceutical policy in the U.S. Congressional debate about incentives for the development of new counter-bioterrorism treatments; Pressure on Food and Drug Administration officials to address concerns about access to quality biotechnology products; Importance of manufacturing...

  • GMP Yield-Considerations Beyond Percent Theoretical Yield. Pluta, Paul // Journal of GXP Compliance;Summer2010, Vol. 14 Issue 3, p76 

    The article discusses compliance to U.S. Food and Drug Administration (FDA) good manufacturing practice (GMP) yield regulations. According to the authors, meeting them is not necessarily indicative of a well-controlled manufacturing process. Under the regulations, a statement of the actual yield...

  • Adjusting FDA policies to address bioterrorist threat. Fox, Jeffrey L. // Nature Biotechnology;Apr99, Vol. 17 Issue 4, p323 

    Focuses on challenges facing officials at the U.S. Food and Drug Administration (FDA) in making policy changes to combat the threat of bioterrorism in the country. Challenges facing FDA in evaluating vaccines to protect against bioterrorist-inflicted diseases; Changes in policy being...

  • Bioterrorism Page Opens Door to Information. Henkel, John // FDA Consumer;Jan/Feb2002, Vol. 36 Issue 1, p34 

    Presents information on a Web site created by the United States Food and Drug Administration that links to background about bioterrorism and offers a quick study on the subject.

  • The Complexity of Compliance in IVD Manufacturing. Lokas, K. // Medical Device Technology;Dec2005, Vol. 16 Issue 10, p26 

    This article focuses on different issues related to compliance in in vitro diagnostic (IVD) manufacturing industry in the U.S. To grow within the life sciences manufacturing industry, IVD product manufacturers need to reduce variability and cost. They also have to ensure that products get to...

  • Roundtable Q&A Testing & FDA Compliance.  // Medical Design Technology;Mar2011, Vol. 15 Issue 2, p20 

    The article presents questions and answers related to the issues with health device testing and U.S. Food and Drug Administration (FDA) compliance including the tips for device manufacturers to ensure their product testing processes are accurate, what is the common error does medical device...

  • Are You Gambling With Your Next Inspection? Larsen, Julie // Contract Pharma;Nov/Dec2012, Vol. 14 Issue 9, p72 

    The article offers information on the 10 key questions to assess preparedness for a U.S. Food & Drug Administration (FDA) inspection. It mentions that one should be aware of the FDA inspection trends, review processes and correlate the preparation efforts with FDA trends, and address potential...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics